A large supplement market rests on one idea: certain fibers make your body release its own GLP-1, so you feel full without an injection. The pricing side of that market is covered in the supplements nobody prices. A pre-registered scoping review went looking for the human trial evidence behind the claim[1].
It found 52 studies across 1,085 participants, with a median of 19 people per study. Fibers can indeed raise circulating GLP-1 through fermentation in the gut — that part is not in dispute. The question is whether the rise does anything.
The shape of the evidence explains why. Seventy-one percent of the included studies were acute interventions, measuring blood levels and reported fullness in the hours after a single dose. That is a reasonable way to study a mechanism and a poor way to study weight management, which happens over months. No weight outcome was pooled anywhere in the review, so nothing here compares fiber to a drug on the thing people are buying either for.
One fiber category stood out. Dextrins showed effects on both GLP-1 and satiety, across four and five positive studies respectively, which the authors describe as promising for future research. Beta-glucans and mannans each moved one outcome or the other without moving both. Those counts are small enough that a single additional trial could change the picture.
The context the authors give is worth noting, because it is more interesting than the supplement pitch. They frame this as relevant to people tapering off GLP-1 drugs rather than avoiding them — a use case that matters given how much weight returns after stopping, as the two regain numbers and two thirds stop within a year describe. Whether fiber helps with that is untested, but it is at least a sensible question, which is more than can be said for selling it as a substitute. What the actual drugs cost, for comparison, is in what a GLP-1 actually costs.